Hair shedding is one of the most commonly reported but least-addressed sequelae of GLP-1-related weight loss, and it often overlaps with menopausal female pattern hair loss in the same patient. Aesthetic providers who can identify both presentations and offer structured interventions have a meaningful clinical and practice expansion opportunity.
BMI alone misses many high-risk patients. OBSCORE, a new Nature Medicine tool validated in approximately 200,000 participants, gives medical weight management providers a more precise framework for prioritizing interventions.
Medical weight management providers have already figured out that the real revenue expansion in GLP-1 programs comes from the body contouring services layered on after significant weight loss. Aesthetic providers — already equipped with the skills and tools to serve these patients — are only starting to catch on.
May 2026 brought a wave of new clinical data and market shifts that underscore a critical reality: prescribing a GLP-1 is only the beginning of obesity care. From managing the “off-ramp” of weight regain to addressing the complex reality of muscle mass changes, the need for structured, physician-led weight management programs has never been clearer.
April 2026 brought a wave of regulatory and clinical developments that GLP-1 providers need to act on before summer. From a landmark FDA compounding proposal to the Medicare GLP-1 Bridge program’s July 1 launch, here is what changed and what it means for your practice.
March 2026 delivered some of the most consequential GLP-1 news of the year — from a sweeping FDA enforcement action against telehealth compounders to the approval of Foundayo, the first oral GLP-1 with no food or water restrictions. Here’s what every provider needs to know this month.
February 2026 brought a wave of GLP-1 developments relevant to providers running or building a medical weight loss practice — from the expanding oral treatment landscape and a tightening regulatory environment around compounded alternatives, to new clinical evidence on nutritional deficiencies and muscle loss in long-term users. This month’s update covers what the research says and what it means for how you structure and deliver care.
January 2026 brought major GLP-1 updates, from the launch of the first oral Wegovy pill to a new federal insurance model that contrasts sharply with growing state-level restrictions. This roundup synthesizes the key clinical and regulatory news, providing practice-focused takeaways on what providers need to know about the evolving landscape.
The World Health Organization’s endorsement of GLP-1 therapies for obesity treatment adds significant global validation to what providers already know: medical weight management continues to evolve with new clinical data, expanded treatment options, and refined care models. This update summarizes the four most clinically relevant developments shaping your practice and patient outcomes.
The World Health Organization’s endorsement of GLP-1 therapies for obesity treatment adds significant global validation to what providers already know: medical weight management continues to evolve with new clinical data, expanded treatment options, and refined care models. This update summarizes the four most clinically relevant developments shaping your practice and patient outcomes.